Antimicrobial resistance (AMR) is a serious global health threat with dwindling and ineffective treatment options. Currently 26% of infections in Canada are resistant to first line antibiotics and this proportion is expected to increase by 40% in 2050. While several novel antibiotics have been approved in other markets, they are often not available in Canada. When they are available, they are not used due to administrative or market access barriers.
For more information on the current antibiotic landscape in Canada and proposed solutions to increase access to new antibiotics in this country, please consult the McMaster University - Canadian Antimicrobial Innovation Coalition (CAIC) report led by Lori Burrows and several colleagues from McMaster University and CAIC. The report, entitled Antibiotic Access & Capacity Proposal, resulted in a set of 30 concise recommendations, which were submitted to Health Canada and the Public Health Agency of Canada, (PHAC) at the end of 2021 to improve antibiotic access in Canada.
Following this and previous CCA 2029 work on the socio-economic impacts of AMR in Canada, the CCA, at the request of PHAC, recently formed an expert panel, led by Dr. Andrew Morris of the University of Toronto to answer the question: What economic pull incentives have the greatest potential for success in encouraging the market entry and sustained market availability of high-value antimicrobials for use in humans in Canada?